<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01856283</url>
  </required_header>
  <id_info>
    <org_study_id>PhilosoPhy34 CAMN107EIT11T</org_study_id>
    <nct_id>NCT01856283</nct_id>
  </id_info>
  <brief_title>Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells</brief_title>
  <official_title>An Open Label, Single Arm, Phase II Study of Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients, in Order to Verify Disappearance of CD34+/Lin-Ph+ Cells From Bone Marrow During Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Niguarda Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Niguarda Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicentre, single-arm study of nilotinib 300 mg BID in newly diagnosed patients&#xD;
      with CP-CML. This study is designed to establish the disappearance of Ph+ stem cells&#xD;
      (CD34+/lin-) in BM during nilotinib treatment.&#xD;
&#xD;
      In addition, in this study the investigators aim to perform Gene Expression Profiling (GEP)&#xD;
      of CML enrolled patients using Affymetrix GeneChip Instruments and Software Systems, and&#xD;
      Affymetrix GeneChip Human Genome U133 Plus 2.0 (whole human transcriptome analysis) at&#xD;
      diagnosis and at 3 different time points during treatment with Nilotinib (after 3, 6, 12&#xD;
      months).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to establish the disappearance of Ph+ stem cells (CD34+/lin-) in BM&#xD;
      during nilotinib treatment.&#xD;
&#xD;
      The primary efficacy endpoint is to measure the rate of CD34+/lin-Ph+ cells in the BM after 6&#xD;
      months of treatment. In order to obtain this result, BM blood of all enrolled patients will&#xD;
      be stored after 6 months of treatment with nilotinib. The isolated CD34+/lin- cells will be&#xD;
      employed for standard FISH analysis. These endpoints will be obtained at the central&#xD;
      laboratory of Niguarda Ca' Granda Hospital, Milano, Italy.&#xD;
&#xD;
      Secondary endpoints will be reached performing:&#xD;
&#xD;
        -  the same analyzes on CD34+/lin- cells at diagnosis, at 3 and 12 months of treatment;&#xD;
&#xD;
        -  cytogenetic analysis to estimate the rate of CCyR at 3, 6 and 12 months; this analysis&#xD;
           will be performed at each local laboratory;&#xD;
&#xD;
        -  molecular analysis to determinate the rate of MR (≤ 10%, ≤ 1%, MMR, MR4,5 IS) at 3, 6&#xD;
           and 12 months in the peripheral blood; the molecular analysis will be performed using&#xD;
           the Labnet standardized laboratories in Lombardy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2013</start_date>
  <completion_date type="Actual">January 2021</completion_date>
  <primary_completion_date type="Actual">July 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CD34+/lin-Ph+ cells</measure>
    <time_frame>6 month</time_frame>
    <description>To measure the rate of CD34+/lin-Ph+ cells in the BM after 6 months of treatment. In order to obtain this result, BM blood of all enrolled patients (see Appendix&#xD;
1) will be stored after 6 months of treatment with nilotinib. The isolated CD34+/lin- cells will be employed for standard FISH analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CD34+/lin- cells (composite measure)</measure>
    <time_frame>12 month</time_frame>
    <description>Secondary endpoints will be reached performing:&#xD;
the same analyzes on CD34+/lin- cells at diagnosis, at 3 and 12 months of treatment;&#xD;
cytogenetic analysis to estimate the rate of CCyR at 3, 6 and 12 months; this analysis will be performed at each local laboratory; molecular analysis to determinate the rate of MR (≤ 10%, ≤ 1%, MMR, MR4,5 IS) at 3, 6 and 12 months in the peripheral blood; the molecular analysis will be performed using the Labnet standardized laboratories in Lombardy.&#xD;
The Outcome Measure indicates that the measure is a composite.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">87</enrollment>
  <condition>Leukemia, Myeloid, Chronic-Phase</condition>
  <arm_group>
    <arm_group_label>Nilotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>study of nilotinib 300 mg BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nilotinib 300mg BID</intervention_name>
    <description>Nilotinib</description>
    <arm_group_label>Nilotinib</arm_group_label>
    <other_name>Nilotinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients with diagnosis of CP-CML with cytogenetic confirmation of Ph&#xD;
             chromosome (9;22) translocation within 3 months of diagnosis&#xD;
&#xD;
          -  Patients Ph negative or with variant translocations by standard cytogenetic analysis&#xD;
             but Ph positive by FISH, are eligible as well&#xD;
&#xD;
          -  Age ≥ 18 years old (no upper age limit given)&#xD;
&#xD;
          -  WHO performance status ≤2&#xD;
&#xD;
          -  Normal serum levels ≥ LLN (lower limit of normal) of potassium, magnesium, total&#xD;
             calcium corrected for serum albumin or phosphorus, or correctable to within normal&#xD;
             limits with supplements, prior to the first dose of study medication&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 x ULN or ≤ 5.0 x ULN if considered due to leukaemia&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 x ULN unless considered due to leukaemia&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 x ULN, except know Mb Gilbert&#xD;
&#xD;
          -  Serum lipase and amylase ≤ 1.5 x ULN&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 x ULN&#xD;
&#xD;
          -  Written informed consent signed prior to any study procedures being performed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pre-treatment with HU for &gt; 3 months and with imatinib is not permitted&#xD;
&#xD;
          -  Prior accelerated phase including clonal evolution or blast crisis&#xD;
&#xD;
          -  Contraindication to excipients in study medication&#xD;
&#xD;
          -  impaired cardiac function including any of the following:&#xD;
&#xD;
               1. LVEF &lt;45%&#xD;
&#xD;
               2. Complete left bundle branch block&#xD;
&#xD;
               3. Right bundle branch block plus left anterior hemiblock,bifascicular block&#xD;
&#xD;
               4. Use of a ventricular-paced pacemaker&#xD;
&#xD;
               5. Congenital long QT syndrome&#xD;
&#xD;
               6. Clinically significant ventricular or atrial tachyarrhythmias&#xD;
&#xD;
               7. Clinically significant resting bradycardia (&lt;50 beats per minute)&#xD;
&#xD;
               8. QTcF &gt;450 msec on screening ECG.If QTcF &gt;450 msec and electrolytes are not within&#xD;
                  normal ranges before nilotinib dosing, electrolytes should be corrected and then&#xD;
                  the patient rescreened for QTcF criterion&#xD;
&#xD;
               9. Myocardial infarction within 12 months prior to starting nilotinib&#xD;
&#xD;
              10. Other clinical significant heart disease (e.g. unstable angina,congestive heart&#xD;
                  failure,uncontrolled hypertension)&#xD;
&#xD;
          -  Acute (i.e. within 1 year of starting study medication) or chronic pancreatitis&#xD;
&#xD;
          -  Concurrent uncontrolled medical conditions (e.g. uncontrolled diabetes, active or&#xD;
             uncontrolled infections,acute or chronic liver and renal disease) that could cause&#xD;
             unacceptable safety risks or compromise compliance with the protocol&#xD;
&#xD;
          -  Impaired gastrointestinal function or disease that may alter the absorption of study&#xD;
             drug (e.g.ulcerative disease,uncontrolled nausea,vomiting and diarrhea,malabsorption&#xD;
             syndrome,small bowel resection or gastric by-pass surgery)&#xD;
&#xD;
          -  Concomitant medications with potential QT prolongation (see link for complete list:&#xD;
             http://www.torsades.org/medical-pros/drug-lists/printable-drug-list.cfm)&#xD;
&#xD;
          -  Concomitant medications known to be strong inducers or inhibitors of the CYP450&#xD;
             Isoenzyme CYP3A4:see link for complete list&#xD;
             (http://medicine.iupui.edu/flockhart/table.htm)&#xD;
&#xD;
          -  Patients who have undergone major surgery ≤ 2 weeks prior to starting study drug or&#xD;
             who have not recovered from side effects of such therapy&#xD;
&#xD;
          -  Patients who are pregnant or breast feeding or women of reproductive potential not&#xD;
             employing an effective method of birth control.Women of childbearing potential must&#xD;
             have a negative serum pregnancy test within 14 days prior to administration of&#xD;
             nilotinib.Post menopausal women must be amenorrheic for at least 12 months in order to&#xD;
             be considered of non-childbearing potential.Female patients must agree to employ an&#xD;
             effective barrier method of birth control throughout the study and for up to 3 months&#xD;
             following discontinuation of study drug&#xD;
&#xD;
          -  Treatment with any haematopoietic colony-stimulating growth factors (e.g. G-CSF,&#xD;
             GM-CSF) ≤1 week prior to starting study drug&#xD;
&#xD;
          -  Known diagnosis of human immunodeficiency virus (HIV) infection (HIV testing is not&#xD;
             mandatory)&#xD;
&#xD;
          -  Patients with a history of another primary malignancy that is currently clinically&#xD;
             significant or currently requires active intervention&#xD;
&#xD;
          -  Patients unwilling or unable to comply with the protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ester Pungolino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Niguarda Ca' Granda Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>A.O. Ospedale S. Antonio</name>
      <address>
        <city>Gallarate</city>
        <state>Milano</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Desio- &quot;Ospedale Civile&quot; di Vimercate, Desio, Carate Brianza, Giussano, Seregno.</name>
      <address>
        <city>Vimercate</city>
        <state>Milano</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O di Circolo di Busto Arsizio</name>
      <address>
        <city>Busto Arsizio</city>
        <state>Varese</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti Bergamo</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spedali Civili Brescia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Valduce</name>
      <address>
        <city>Como</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituti Ospitalieri di Cremona</name>
      <address>
        <city>Cremona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O Ospedale Lecco</name>
      <address>
        <city>Lecco</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>Italy</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O Sacco</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto dei Tumori</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo Oncologia</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Paolo</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S. Gerardo di Monza</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico S.Matteo Pavia</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Fondazione Macchi</name>
      <address>
        <city>Varese</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>May 14, 2013</study_first_submitted>
  <study_first_submitted_qc>May 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2013</study_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

